However, Defactinib‐treated mice presented a significant decrease in tumor size and weight compared to vehicle‐treated counterparts (Fig. 6H), and this decrease was accompanied with a decrease in p‐FAK‐Y397 levels as assessed by immunohistochemistry (Fig. 6I). Here, PTK2 is linked to neoplasm.